Table 4 shows the relationships between mortality and selected variables. After a median follow-up of 21 days (IQR: 13–41), 13 patients had died (38.2%), 17 had recovered (50.0%) and four (11.7%) were still infected. Most of the deceased patients (11/13) were receiving ADT plus additional PC treatment: enzalutamide (n = 5), docetaxel (n = 3), abiraterone (n = 2) and cabazitaxel (n = 1). All were symptomatic at the time of diagnosis, and most (10/13) were hospitalised. The deaths occurred a median of nine days (IQR: 4–20) after the diagnosis of COVID-19.
Table 4 Relationships between mortality and selected variables.
Variable Alive # (%) Dead # (%) P value
Status at the prostate cancer diagnosis
 Localised disease 13 (65.0%) 7 (35.0%) NS
 Metastatic disease 8 (57.1%) 6 (42.9%)
Presence of visceral metastases
 Yes 4 (57.1%) 3 (42.9%) NS
 No 17 (63.0%) 10 (37.0%)
Ongoing administration of steroids
 Yes 10 (62.5%) 6 (37.5%) NS
 No 11 (61.1%) 7 (38.9%)
No. of previously administered treatments for mCRPC
 0–1 20 (74.1%) 7 (25.9%) 0.004
 ≥2 1 (14.3%) 6 (85.7%)
Ongoing treatment for mCRPC
 None 4 (66.7%) 2 (33.3%) NS
 ARTA 12 (63.2%) 7 (36.8%)
 Chemotherapy 5 (55.6%) 4 (44.4%)
Pre-existing comorbidities
 0 7 (77.8%) 2 (22.2%) NS
 1–2 12 (60.0%) 8 (40.0%)
 ≥2 2 (40.0%) 3 (60.0%)
Alive median (IQR) Dead median (IQR) P value
Age (years) 75 (68–81) 75 (69–83) NS
Time between PC diagnosis and infection onset (months) 62 (20–107) 69 (43–139) NS
Length of ADT exposure (months) 39 (17–62) 57 (34–115) NS
ADT = androgen deprivation therapy; IQR = interquartile range; mCRPC = metastatic castration-resistant prostate cancer; NS = not significant; PC = prostate cancer; COVID = coronavirus disease 2019.